Recently, Chinese nucleic acid drug delivery and RNA drug R&D startup MagicRNA announced that it has completed the angel round of financing of tens of millions of yuan. This round of financing will accelerate the construction process of MagicRNA's 2500 square meter R&D center and GMP grade pilot base, and lay a solid foundation for the investigator-initiated trial (IIT) to be carried out in the second half of 2022 and the investigational new drug (IND) application in the first half of 2023.

MagicRNA is an RNA drug innovation enterprise, which was established in 2021. The company has the largest ionizable amino lipid library in China with completely independent intellectual property rights. The delivery system developed by MagicRNA has reached the domestic leading level according to in vivo activity and scalability (120 ml/min). It has applied for a number of invention patents and has been authorized with two invention patents. The R&D center and GMP grade pilot base with a total area of 2500 square meters will be put into operation in September 2022.

MagicRNA has gathered top talents in the industry, including 5 doctors (postgraduates) and 16 masters, and has built five platforms: bioinformatics center, mRNA synthesis and technology center, LNP preparation technology center, drug nonclinical evaluation center, and IND drug registration and clinical research center. Guided by clinical needs, MagicRNA focuses on RNA technology to overcome clinically incurable diseases and aims to become an excellent pharmaceutical enterprise with innovative R&D and industrial transformation as the dual-core. At present, many mRNA drugs of MagicRNA have been in the stage of preclinical research.